Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lipids in 2012

HDL cholesterol studies—more of the same?

Studies published in 2012 in the field of HDL research have provided further evidence suggesting that a low HDL-cholesterol level, in the absence of related lipid or nonlipid risk factors, is not associated with increased risk of coronary heart disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Mechanisms linking HDL to cardiovascular disease.


  1. Després, J. P., Lemieux, I., Dagenais, G. R., Cantin, B. & Lamarche, B. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 153, 263–272 (2000).

    Article  Google Scholar 

  2. Brewer, H. B. Jr. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J. Clin. Endocrinol. Metab. 96, 1246–1257 (2011).

    Article  CAS  Google Scholar 

  3. Barter, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53, 1755–1766 (2012).

    Article  CAS  Google Scholar 

  4. Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007).

    Article  CAS  Google Scholar 

  5. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).

    Article  CAS  Google Scholar 

  6. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).

    Article  CAS  Google Scholar 

  7. Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572–580 (2012).

    Article  CAS  Google Scholar 

  8. Mackey, R. H. et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 60, 508–516 (2012).

    Article  CAS  Google Scholar 

  9. Parish, S. et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 125, 2469–2478 (2012).

    Article  CAS  Google Scholar 

  10. Arsenault, B. J. & Després, J. P. Lipids: HDL cholesterol is not HDL—don't judge the book by its cover. Nat. Rev. Cardiol. 9, 557–558 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

J.-P. Després has received honoraria from Abbott, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer Canada, and has acted as a consultant for Novartis, Sanofi, Theratechnologies, and Torrent Pharmaceuticals.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Després, JP. HDL cholesterol studies—more of the same?. Nat Rev Cardiol 10, 70–72 (2013).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing